Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-101 in healthy volunteers
NCT07334249Phase 1Not yet recruiting
- Sponsor
- SynphaTec
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing SP-101 Injection with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 28 days. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
SP-101
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07334249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07334249.